EXELIXIS INC (EXEL)       17.505  -0.05 (-0.31%)

17.505  -0.05 (-0.31%)

US30161Q1040 - Common Stock

EXELIXIS INC17.505

NASDAQ:EXEL (2/2/2023, 8:50:10 AM)-0.05 (-0.31%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-01 2022-11-01/amc Earnings (Next) 02-15 2023-02-15
Ins Owners 1.59% Inst Owners 85.45%
Market Cap 5.65B Shares 322.56M
PE 18.43 Fwd PE 17.57
Dividend Yield N/A Analysts 81.82
IPO 04-11 2000-04-11

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

EXEL Daily chart

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. The company is headquartered in Alameda, California and currently employs 954 full-time employees. The company went IPO on 2000-04-11. The firm is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Company Info

EXELIXIS INC

1851 Harbor Bay Parkway

Alameda CALIFORNIA 94502

P: 16508377000.0

CEO: Michael M. Morrissey

Employees: 954

Website: https://www.exelixis.com/

EXEL News

News Image9 days ago - Exelixis, Inc.Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023News Image13 days ago - Market News VideoFirst Week of March 17th Options Trading For Exelixis (EXEL)News Image14 days ago - Exelixis, Inc.Exelixis Announces Update on Patent Litigation with MSN LaboratoriesNews Image14 days ago - Seeking AlphaExelixis has mixed ruling in Cabometyx patent trial, wins on 2026, lost on 2030

Exelixis (EXEL) had a mixed ruling in its Cabometyx patent trial versus MSN Laboratories

News Image15 days ago - InvestorPlace7 Biotech Stocks That Will Make You Rich in 10 Years

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

News Image25 days ago - Exelixis, Inc.Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

EXEL Twits

Here you can normally see the latest stock twits on EXEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example